Navigation Links
Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
Date:12/14/2009

erty protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize ovarian cancer diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop ovarian cancer diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future ovarian cancer diagnostic products; (5) uncertainty of market acceptance of its OVA1 diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (6) uncertainty that Vermillion will successfully license or otherwise successfully partner its products; (7) uncertainty that Vermillion will have the resources to successfully complete its bankruptcy reorganization; (8) uncertainty as to whether operating under Chapter 11 may harm our business; (9) uncertainty regarding whether we will be able to obtain confirmation of a Chapter 11 plan of reorganization; (10) uncertainty as to whether we will be able to emerge from bankruptcy without being liquidated or obtain the necessarily funding to continue as a going concern; (11) uncertainty whether a plan of reorganization may result in holders of our common stock receiving no or limited distributions on account of their interests and cancellation of their common stock; (12) uncertainty whether operating under the U.S. Bankruptcy Code may restrict our ability to pursue our business strategies and identify and develop additional diagnostic products; (13) uncertainty whether the trading in our stock will become significantly less liquid or our ability to relist on shares on the Nasdaq Global Sele
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... ON, July 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... additional,restructuring plans to further reduce its cash burn ... strategic alternatives that may,include potential acquisitions and mergers. ... completed an extensive review of its VP,series of ...
... NEW BRUNSWICK, N.J., July 3 Senesco,Technologies, Inc. ... announced today,that it has contracted with Polyplus-transfection (Illkirch, ... of Senesco,s,combination therapy of siRNA against Factor 5A ... Senesco has previously reported positive preclinical in vivo ...
... 3 Antigen Discovery Inc. ("ADI",formerly ImmPORT Therapeutics ... advanced genomics and proteomics tools,announced today that the ... the,National Institute of Allergy and Infectious Diseases (NIAID) ... $3 million grant will,fund efforts to further develop ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
(Date:7/24/2014)... multi-institutional team of researchers has developed a new nanoscale ... noninvasive method for assessing the function and properties of ... better diagnosis and treatment of gut diseases. ... bowel syndrome and inflammatory bowel disease all occur in ... in patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... low levels of particulate air pollution may increase the ... suggest current exposure standards could be insufficient to protect ... public is exposed to ambient air pollution at the ... suggesting a potentially large public health impact," said Lynda ...
... People with highly developed emotional sensibilities are better at ... the Journal of Consumer Research. "Consumers who understand ... such as health decisions and product choices," explain the ... Childers (University of Kentucky). "A person can know a ...
... Medical Research, led by Jos Luis Milln, Ph.D., have ... replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal ... foundation for future clinical trials for HPP patients. ... that most commonly results from a lack of vitamin ...
Cached Biology News:Even low levels of air pollution may pose stroke risk 2Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
Request Info...
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
...
Normal human AB serum, pooled...
Biology Products: